Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BMRA | US
-0.05
-2.54%
Healthcare
Diagnostics & Research
31/08/2024
06/03/2026
1.92
1.95
1.95
1.87
Biomerica Inc. a biomedical technology company develops patents manufactures and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood urine nasal or fecal specimens from patients in the diagnosis of various diseases food intolerances and other medical complications; or to measure bacteria hormones antibodies antigens or other substances which may exist in the human body stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases food intolerances and various esoteric tests at the physicians' offices and over-the-counter drugstores and hospital/clinical laboratories. The company is also developing InFoods that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; Helicobacter pylori test that indicates if a patient is infected with the H. Pylori bacteria. In addition it develops products to indicate if a person has been infected by COVID-19. Biomerica Inc. was incorporated in 1971 and is headquartered in Irvine California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.1%1 month
48.7%3 months
52.7%6 months
49.7%-
-
1.07
0.13
0.09
-5.42
0.65
-
-6.42M
32.30M
32.30M
-
-75.71
-
5.50
-76.48
0.47
2.81
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.37
Range1M
0.57
Range3M
1.07
Rel. volume
1.21
Price X volume
35.85K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| STAR EQUITY HOLDINGS INC | STRR | Diagnostics & Research | 10.07 | 32.44M | 0.20% | n/a | 26.85% |
| MYnd Analytics Inc | MYND | Diagnostics & Research | 0.4269 | 19.49M | 1.62% | n/a | 117.50% |
| VolitionRx Limited | VNRX | Diagnostics & Research | 0.1981 | 18.25M | 0.66% | n/a | -26.88% |
| Mainz Biomed B.V. Ordinary Shares | MYNZ | Diagnostics & Research | 0.83 | 18.17M | 2.29% | n/a | 228.39% |
| bioAffinity Technologies Inc. | BIAF | Diagnostics & Research | 1.04 | 14.03M | 0.97% | n/a | 40.20% |
| INOTIV INC | NOTV | Diagnostics & Research | 0.3691 | 9.60M | 11.17% | n/a | 236.01% |
| XWEL | XWEL | Diagnostics & Research | 1.32 | 6.94M | -8.97% | n/a | 126.14% |
| Trinity Biotech plc | TRIB | Diagnostics & Research | 0.7288 | 6.90M | -0.16% | n/a | 0.00% |
| T2 Biosystems Inc | TTOO | Diagnostics & Research | 0.01 | 174.80K | 0.05 | -325.87% | |
| iSpecimen Inc. Common Stock | ISPC | Diagnostics & Research | 0.2487 | 162.86K | 0.69% | n/a | 0.48% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.21 | 32.29M | -3.49% | 0.03 | 16.03% |
| Reading International Inc | RDI | Media - Diversified | 0.9993 | 28.21M | -2.98% | n/a | 4054.78% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6345 | 12.26M | -10.63% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.4799 | 3.78M | -0.68% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.397 | 3.78M | -1.73% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -3.24% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.42 | - | Cheaper |
| Ent. to Revenue | 0.65 | - | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 1.07 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 52.70 | - | Par |
| Debt to Equity | 0.13 | -14.36 | Expensive |
| Debt to Assets | 0.09 | 0.34 | Cheaper |
| Market Cap | 32.30M | - | Emerging |